Telix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares

Simply Wall St.

Jul 31

Global markets are sending mixed signals, with solid growth pockets, uneven inflation trends, and interest rate paths that still keep investors on their toes. In this kind of backdrop, growth stocks ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2655382433"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655382433\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655382433?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","is_english":true,"pubTime":"2026-07-31 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655382433","market":"nz","top_or_hot":-1,"title":"Telix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares","media":"Simply Wall St.","content":"<div>\n<p>Global markets are sending mixed signals, with solid growth pockets, uneven inflation trends, and interest rate paths that still keep investors on their toes. In this kind of backdrop, growth stocks ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-and-2-fast-growing-insider-owned\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-31 06:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-and-2-fast-growing-insider-owned><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Global markets are sending mixed signals, with solid growth pockets, uneven inflation trends, and interest rate paths that still keep investors on their toes. In this kind of backdrop, growth stocks ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-and-2-fast-growing-insider-owned\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX","symbol_name":"Telix Pharmaceuticals Ltd. (Uplisting)","start_time":0,"source_url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-and-2-fast-growing-insider-owned","article_id":"2655382433","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pdi/predictive-discovery-shares/news/telix-pharmaceuticals-stock-and-2-fast-growing-insider-owned","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655382433","pubTimestamp":1785450195,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Global markets are sending mixed signals, with solid growth pockets, uneven inflation trends, and interest rate paths that still keep investors on their toes. In this kind of backdrop, growth stocks where insiders own a lot of shares can be especially interesting. Management and large shareholders have more of their own capital on the line, which can help align decisions with outside investors. This article focuses on fast growing stocks with high insider ownership, supported by outlooks from...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","PDI.AU":"PREDICTIVE DISCOVERY LTD","BK4139":"生物科技","BK7067":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7095":"多种金属与采矿","LIN.AU":"LINDIAN RESOURCES LTD","BK7104":"黄金"},"translate_title":"Telix Pharmaceuticals 股票和 2 只快速增长的内部人士持有的 ASX 股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIN.AU":1,"TLX.AU":1,"TLX":1.5,"PDI.AU":1},"content_text":"Global markets are sending mixed signals, with solid growth pockets, uneven inflation trends, and interest rate paths that still keep investors on their toes. In this kind of backdrop, growth stocks where insiders own a lot of shares can be especially interesting. Management and large shareholders have more of their own capital on the line, which can help align decisions with outside investors. This article focuses on fast growing stocks with high insider ownership, supported by outlooks from both analysts and company leadership. You will see three of the most notable stocks from this screener and the key reasons they stand out in the current environment. AdvertisementPredictive Discovery (ASX:PDI) Overview: Predictive Discovery is an Australian gold company focused on exploring and developing gold deposits in West Africa, with its flagship Bankan Gold project covering 356 square kilometers in north east Guinea. The company aims to turn its resource and reserve base into long life producing assets supported by two existing mines in the region. Market Cap: A$3.1b Predictive Discovery gives you exposure to a West African gold platform that combines two producing mines with the large Bankan project. Analysts currently forecast a transition from no revenue to a larger operating scale over time. The company is included in analyst forecasts for both revenue and earnings, and some analysts view the current share price as below their intrinsic value estimates. At the same time, Predictive Discovery is loss making, has a short cash runway and relies on higher risk borrowing, while insiders have sold shares recently. The proposed name change to PDI Gold and capital consolidation add another layer that investors focusing on governance, funding needs and strategic plans may want to assess closely. Predictive Discovery’s shift from early stage explorer to potential producer has investors asking what comes next, and the real insight sits in the detailed analysis report for Predictive Discovery ASX:PDI Earnings & Revenue Growth as at Jul 2026 Telix Pharmaceuticals (ASX:TLX) Overview: Telix Pharmaceuticals develops and commercialises radiopharmaceutical products that help doctors image and treat cancers more precisely, using targeted radioactive agents as both diagnostic tools and therapies. Its portfolio spans prostate, kidney and brain cancers, supported by late stage clinical trials and a growing footprint across major markets such as the United States, Europe and Asia. Operations: Telix generates most of its revenue from Precision Medicine at about US$621.9m, with Manufacturing Solutions contributing roughly US$245.1m and Therapeutics about US$9.3m, partly offset by US$72.5m of inter segment eliminations. Market Cap: A$4.8b Telix Pharmaceuticals is attracting attention because it already has a sizeable commercial imaging franchise, anchored by Illuccix and Gozellix across 20 plus countries, while also pushing a deep therapeutics pipeline for prostate, kidney and brain cancers through multiple Phase 3 trials. Recent quarterly revenue of US$247m, raised 2026 guidance of US$950m to US$970m and a new Regeneron partnership highlight how the platform is scaling. However, the stock has previously seen sharp price declines and still carries funding, trial and regulatory risks, including an SEC subpoena and FDA delays. Analysts and Simply Wall St see meaningful upside potential, but the real question is how the valuation stacks up once you factor in expected profitability and execution risk over the next few years. Telix Pharmaceuticals looks like a growth story that might be masking more than it reveals. Before you assume the current pipeline and guidance are fully reflected in the share price, scan the analyst forecasts for Telix Pharmaceuticals and see what could change the script next. ASX:TLX Earnings & Revenue Growth as at Jul 2026 Lindian Resources (ASX:LIN) Overview: Lindian Resources is a Perth based miner focused on exploring and developing rare earths, bauxite and gold projects across Africa and Australia, with its flagship Kangankunde Rare Earths project in Malawi aimed at supplying key materials for electric vehicles, wind turbines and other high tech applications. Market Cap: A$1.32b Lindian Resources is on many growth watchlists because analysts expect very large jumps in both earnings and revenue over the next few years, with the company forecast to move from losses to profitability. The first production blast at Kangankunde in July 2026 and plans for initial output by Q4 2026 give this story real operational momentum, supported by a new Singapore office to handle global sales of rare earth products. The flip side is real risk. Lindian is still loss making, has relied on dilution and higher risk borrowing, and is led by a relatively new and less experienced board and management team. That mix of high growth expectations and early stage governance is exactly what investors need to weigh up carefully. Lindian Resources looks like an accelerating rare earths story that many investors may still be underestimating. Before assuming the early stage risks are fully priced in, scan the analyst forecasts for Lindian Resources and see what the market might be missing next ASX:LIN Earnings & Revenue Growth as at Jul 2026 The three stocks in this article are only a small sample. The full screener surfaces 100 more fast growing companies with high insider ownership that each have their own compelling narrative, all captured in the Fast Growing Stocks With High Insider Ownership screener. Use Simply Wall St to identify and analyze the specific catalysts, insider signals and growth stories that match your highest conviction ideas so you can focus on the opportunities that fit your own criteria. Take Control of Your Investment Journey  If Lindian Resources or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.\n            Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.\n            Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.\n            By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.\n         Seeking Alternatives Before Momentum Flies Fresh stock ideas can move from quiet to breakout quickly. Use this window while it matters and before the crowd catches on. Stay curious and get in early.  Spot income workhorses built for staying power by scanning the 4 dividend fortresses that have been curated for durable payouts and balance sheet resilience. Explore potential tech momentum by reviewing the 56 AI infrastructure stocks that could underpin rising data demand and AI build outs while they are still under the radar for now. Hunt resilient compounding stories by filtering the 9 resilient stocks with low risk scores that combine lower overall risk scores with business models designed to keep moving even when sentiment drops.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Telix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}